DIFFERENTIAL UPTAKE OF IMMUNO-ONCOLOGY (IO) TREATMENTS AMONG DIFFERENT INCOME LEVELS FOR NON-SMALL CELL CANCER PATIENTS IN CHINA

被引：0
|
作者：
De Richter, P. [1 ]
机构：
[1] Ipsos, Kuala Lumpur 14, Malaysia
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN246
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [41] Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
    Kongnakorn, Thitima
    Sarri, Grammati
    Freitag, Andreas
    Marczell, Kinga
    Kazmierska, Paulina
    Masters, Elizabeth
    Pawar, Vivek
    Zhang, Xinke
    [J]. PHARMACOECONOMICS, 2022, 40 (02) : 183 - 201
  • [42] MODELING APPROACHES IN COST-EFFECTIVENESS ANALYSIS (CEA) OF FIRST-LINE (1L) IMMUNO-ONCOLOGY (IO) THERAPIES IN NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Kongnakorn, T.
    Walker, A.
    Sarri, G.
    Freitag, A.
    Marczell, K.
    Kazmierska, P.
    Masters, E.
    Pawar, V
    Zhang, X.
    [J]. VALUE IN HEALTH, 2020, 23 : S446 - S446
  • [43] Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients
    Jiang, Da
    Shi, Jian
    Yuan, Meng
    Duan, Xiaoyang
    Li, Lihua
    Li, Qian
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2018, 64 (06) : 71 - 76
  • [44] THE IMPACT OF RESPONSE AT A LANDMARK ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF THE VALUE OF IMMUNO-ONCOLOGY (I-O) TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Santi, I
    Johal, S.
    Yuan, Y.
    Penrod, J. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S211 - S211
  • [45] Zyxin expression levels in non-small cell lung cancer patients
    Ilic, Dejan
    Rancic, Milan
    Jevtovic, Tatjana Stoimenov
    Petrovic, Veljko
    Petrovic, Marina
    [J]. VOJNOSANITETSKI PREGLED, 2020, 77 (12) : 1309 - 1317
  • [46] Effects of nutritional intervention in non-small cell lung cancer patients with different levels of systemic inflammation
    Droege, W.
    Tozer, R. G.
    Tai, P.
    Ducruet, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Evaluation of progression-free survival (PFS) and one-year (1y) survival as surrogate endpoints (SE) in previously treated advanced non-small cell lung cancer (adNSCLC) in the era of immuno-oncology (IO)
    Zhao, S.
    Zhang, Z.
    Zhou, T.
    Zhang, Y.
    Zhang, L.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 535 - 535
  • [48] Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study
    Bodd, Monica H.
    Locke, Susan C.
    Wolf, Steve P.
    Antonia, Scott
    Crawford, Jeffrey
    Hartman, John
    Herring, Kris W.
    Ready, Neal E.
    Stinchcombe, Thomas E.
    Troy, Jesse D.
    Williams, Chakita
    Clarke, Jeffrey M.
    LeBlanc, Thomas W.
    [J]. LUNG CANCER, 2023, 175 : 17 - 26
  • [49] Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
    Katoh, Masaru
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (09) : 5178 - 5183
  • [50] Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era
    Palmieri, Maria
    Frullanti, Elisa
    [J]. MEDICAL SCIENCES, 2023, 11 (01)
12345